KRAS and colorectal carcinoma: We demonstrate that specific KRAS mutation types, not all KRAS mutation types, are associated with a low density of TILs and that the KRAS mutation subtype is an independent prognostic parameter in patients with stage III CRC treated with oxaliplatin-based adjuvant chemotherapy.